Abstract:Background About 90% of mortality associated with cancer is attributable to metastatic disease. Thus, our ability to treat cancer is largely dependent on the capacity to prevent metastasis. Metabolic reprogramming is recognized to support cellular transformation and tumor initiation; however, whether or how metabolism supports metastasis remains an open question. This study seeks to identify metabolic predictors of metastasis, with the rationale that understanding metabolic changes will lead to novel insights into metastasis and perhaps new therapies to treat metastatic disease. Materials and methods A patient-derived xenograft model was used in which metastasis in mice strongly correlates with metastatic history of patient donors. Tumor cells were originally obtained from melanoma patients and passaged exclusively in highly immunocompromised mice [1]. In this study, 17 of such tumor lines were investigated including 6 lines with low metastatic potential, 9 high metastatic potential and 2 intermediate metastatic potential. Tumor cells were implanted subcutaneously into mice, yielding 62 tumors. 3-4 biopsies from each primary tumor were harvested, for a total of 185 samples. A mass spectrometry (MS)-based analytical platform was used to characterize >150 metabolites in each specimen. The relative abundance of metabolites that contribute most to the distinction of highly metastatic from inefficiently metastatic melanomas was examined using statistical tools. Results Unsupervised hierarchical clustering revealed that in every case, a given tumor biopsy was most closely related to all other biopsies descended from the same parental tumor. In addition, as a frequent mutation in melanoma, BRAFmutant tumors were easily distinguished from BRAF-wild type tumors by their metabolomic signatures. More importantly, several metabolic pathways were found altered significantly when metabolomics profiles between melanoma lines with high or low metastatic potentials were compared. Conclusions The MS-based metabolomic analysis of patient-derived melanoma xenografts demonstrates that tumors contain individual metabolomic identities that can be tracked. It may be possible to identify metabolomic features from primary tumors that predict various aspects of tumor biology, including the propensity to metastasize. The altered metabolic pathways in highly metastatic melanomas are potential therapeutic targets.

Proteomic analysis of two metabolic proteins with potential to translocate to plasma membrane associated with tumor metastasis development and drug targets.

Multimodal Metabolic Imaging Reveals Pigment Reduction and Lipid Accumulation in Metastatic Melanoma

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Identification of Breast Cancer Metastasis‐associated Proteins in an Isogenic Tumor Metastasis Model Using Two‐dimensional Gel Electrophoresis and Liquid Chromatography‐ion Trap‐mass Spectrometry

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Proteomic and Metabolomic Characterization of Bone, Liver, and Lung Metastases in Plasma of Breast Cancer Patients.

Proteomic Study on Multi-Organ Metastases of Human Ovarian Clear Cell Carcinoma Cell Line in a Xenograft Mouse Model Based on a Novel Sequence-Specific Analysis Strategy

Expression of Lipid Metabolism-Related Proteins in Metastatic Breast Cancer

Comparative Proteome Analysis of Three Mouse Lung Adenocarcinoma CMT Cell Lines with Different Metastatic Potential by Two‐dimensional Gel Electrophoresis and Mass Spectrometry

In-Depth Characterization of Mass Spectrometry-Based Proteomic Profiles Revealed Novel Signature Proteins Associated with Liver Metastatic Colorectal Cancers

Integrative Analysis of Membrane Proteome and MicroRNA Reveals Novel Lung Cancer Metastasis Biomarkers

Proteomic Analysis of Differentially Expressed Proteins Between Metastatic and Non-Metastatic Human Colorectal Carcinoma Cell Lines.

Identification of the fatty acid synthase interaction network via iTRAQ-based proteomics indicates the potential molecular mechanisms of liver cancer metastasis

Comprehensive Profiling of Metastasis-Related Proteins in Paired Hepatocellular Carcinoma Cells with Different Metastasis Potentials

Monitoring the Progression of Metastatic Breast Cancer on Nanoporous Silica Chips

Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis

Early and late endothelial response in breast cancer metastasis in mice: simultaneous quantification of endothelial biomarkers using a mass spectrometry-based method

Plasma-based proteomic and metabolomic characterization of lung and lymph node metastases in cervical cancer patients

Identifying Metabolomic Features That Predict Metastasis of Melanoma from a Primary Site

Proteome Analysis of Hepatocellular Carcinoma Cell Strains, MHCC97-H and MHCC97-L, with Different Metastasis Potentials.

Fatty acid synthase promotes breast cancer metastasis by mediating changes in fatty acid metabolism